Recombinant multi-species ATXN1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ATXN1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). Alternative splicing results in multiple transcript variants, with one variant encoding multiple distinct proteins, ATXN1 and Alt-ATXN1, due to the use of overlapping alternate reading frames. [provided by RefSeq, Nov 2017]
The Alternative Names of target: 2900016G23Rik,ATX1,ATXN1,Ataxin-1,Atx1,Atxn1,D6S504E,Gm10786,SCA1,Sca1,Spinocerebellar ataxia type 1 protein,sca1

Target products collectionGo to ATXN1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP11037-Ag-1/ GM-Tg-hg-IP11037-Ag-2 Human ATXN1 protein Human
GM-Tg-rg-IP11037-Ag-1/ GM-Tg-rg-IP11037-Ag-2 Rat ATXN1 protein Rat
GM-Tg-mg-IP11037-Ag-1/ GM-Tg-mg-IP11037-Ag-2 Mouse ATXN1 protein Mouse
GM-Tg-cynog-IP11037-Ag-1/ GM-Tg-cynog-IP11037-Ag-2 Cynomolgus/Rhesus macaque ATXN1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP11037-Ag-1/ GM-Tg-felg-IP11037-Ag-2 Feline ATXN1 protein Feline
GM-Tg-cang-IP11037-Ag-1/ GM-Tg-cang-IP11037-Ag-2 Canine ATXN1 protein Canine
GM-Tg-bovg-IP11037-Ag-1/ GM-Tg-bovg-IP11037-Ag-2 Bovine ATXN1 protein Bovine
GM-Tg-equg-IP11037-Ag-1/ GM-Tg-equg-IP11037-Ag-2 Equine ATXN1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP11037-Ag-1/ GM-Tg-hg-IP11037-Ag-2; GM-Tg-rg-IP11037-Ag-1/ GM-Tg-rg-IP11037-Ag-2;
GM-Tg-mg-IP11037-Ag-1/ GM-Tg-mg-IP11037-Ag-2; GM-Tg-cynog-IP11037-Ag-1/ GM-Tg-cynog-IP11037-Ag-2;
GM-Tg-felg-IP11037-Ag-1/ GM-Tg-felg-IP11037-Ag-2; GM-Tg-cang-IP11037-Ag-1/ GM-Tg-cang-IP11037-Ag-2;
GM-Tg-bovg-IP11037-Ag-1/ GM-Tg-bovg-IP11037-Ag-2; GM-Tg-equg-IP11037-Ag-1/ GM-Tg-equg-IP11037-Ag-2
Products Name ATXN1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name ATXN1
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ATXN1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.